middle.news

Actinogen identifies older-patient signal in mixed XanaMIA Alzheimer’s trial

8:32am on Thursday 19th of November, 2026 AEDT • Biotechnology and Pharmaceuticals
Read Story

Actinogen identifies older-patient signal in mixed XanaMIA Alzheimer’s trial

8:32am on Thursday 19th of November, 2026 AEDT
Key Points
  • Non-significant 0.10-point CDR-SB benefit across the full trial at 36 weeks
  • 40% of participants over 75 had no disease progression versus 22% on placebo
  • Older subgroup showed estimated 30% disease slowing, but this measure was not statistically significant
  • No serious adverse events were attributed to Xanamem over 36 weeks
Read Story
middle.

Tap to Read

Tap the card to read the full analysis
about Actinogen Medical (ASX:ACW)
OPEN ARTICLE